Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Germline Genetic Testing in Patients with Bone and Soft Tissue Sarcoma: A Prospective Multicenter Study to Evaluate Cancer Susceptibility
Ailts, Isaak , Golafshar, Michael A. , Kunze, Katie L. , Klint, Margaret, Barrus, Kathleen , Nussbaum, Robert L., Esplin, Edward D. , Leach, Brandie, Nielsen, Sarah M. , Samadder, N. Jewel , Seetharam, ­Mahesh , Young, Sarah , Golafshar, Michael , Esplin, Edward D , Kunze, Katie L , Leach, Brandie

Mayo Clinic

International Journal of Molecular Sciences | March 21, 2025 | Volume: 26 | Issue: 7 | Pages: 2839

10.3390/ijms26072839 | PMID 40243416 Get It

Sarcomas are rare heterogenous mesenchymal tumors with over seventy-five different subtypes, with varying biology and outcomes, with no clear inciting factor in the vast majority. To determine the prevalence of pathogenic germline variants (PGV) in patients with sarcomas, we undertook a prospective multi-site study of germline sequencing using an 84-gene next-generation sequencing panel among patients receiving care at the four Mayo Clinic Cancer Centers. Of 115 patients with bone and soft tissue sarcoma, the median age was 60 years, 49.6% were female, 82.6% were White. The anatomical location of the primary tumor included extremities (34.8%), retroperitoneum (19.1%), trunk (13.0%), and head and neck (7.8%). Family history of cancer was present in 62.6% of the study population. Ten patients (8.7%) had a pathogenic/likely pathogenic variant (PGV). Of these, three had stage IV sarcoma, and seven had earlier-stage sarcoma (stages I–III). Among the 55 (48.7%) patients who had variant of uncertain significance (VUS), 41.1% (22/55) had stage IV sarcoma and 58.9% (33/55) had earlier-stage disease. Of the ten patients with PGV, high-to-moderate penetrance gene abnormalities were identified in eight patients (80%) involving TP53 (3), BRCA1 (1), SDHA (1), ATM (2), and NBN (1) genes. The vast majority of the PGVs (70%) would not have been detected using the current guidelines. Because of the paucity of sarcomas and lack of effective treatment options for advanced disease, germline testing in sarcomas represents a potentially impactful strategy to assess therapeutic options and for assessment of familial risk.
An unbiased cell-culture selection yields DNA aptamers as novel senescent cell-specific reagents
Jachim, Sarah K. , Prieto, Luis I. , Dugan, Maria , Maher, L. James , Pearson, Keenan S, Doherty, Caroline D, Wilbanks, Brandon A, III, Louis James Maher , Pearson, Keenan , Doherty, Caroline Lloyd , Wilbanks, Brandon , Baker, Darren J. , LeBrasseur, Nathan K.

Mayo Clinic

No container title available | March 19, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.03.19.643361 | PMID 40166138 Get It

ABSTRACT Cellular senescence is an irreversible form of cell-cycle arrest caused by excessive stress or damage. While various biomarkers of cellular senescence have been proposed, there are currently no universal, stand-alone indicators of this condition. The field largely relies on the combined detection of multiple biomarkers to differentiate senescent cells from non-senescent cells. Here we introduce a new approach: unbiased cell culture selections to identify senescent cell-specific folded DNA aptamers from vast libraries of trillions of random 80-mer DNAs. Senescent mouse adult fibroblasts and their non-senescent counterparts were employed for selection. We demonstrate aptamer specificity for senescent mouse cells in culture, identify a form of fibronectin as the molecular target of two selected aptamers, show increased aptamer staining in naturally aged mouse tissues, and demonstrate decreased aptamer staining when p16 expressing cells are removed in a transgenic INK-ATTAC mouse model. This work demonstrates the value of unbiased cell-based selections to identify new senescence-specific DNA reagents.
Novel composite health assessment risk model for older allogeneic transplant recipients: BMT-CTN 1704
Sorror, Mohamed L. , Saber, Wael , Logan, Brent R. , Geller, Nancy L. , Bellach, Anna , Kou, Jianqun, McCarty, John M. , Knight, Thomas G. , Runaas, Lyndsey, Johnston, Laura, Nakamura, Ryotaro , Jarrett, Lori, Mishra, Asmita , Uberti, Joseph P., Morris, Lawrence E. , Nadiminti, Kalyan , Olin, Rebecca L. , Sobecks, Ronald , Wall, Sarah , Mattila, Deborah, Protz, Bailey, Horowitz, Mary M. , Geller, Nancy , Knight, Thomas G , Nakamura, Ryotaro , Dahi, Parastoo B , Saultz, Jennifer N , Imus, Philip H , Hogan, William J , Bhatt, Vijaya Raj , Artz, Andrew S , Sorror, Mohamed , Wood, William A. , Walston, Jeremy D , Jarrett, Lori, McCurdy, Shannon , Hogan, William J. , Bhatt, Vijaya Raj , Maakaron, Joseph E. , Devine, Steven M. , Artz, Andrew

Mayo Clinic

Blood Advances | March 18, 2025 | Volume: 9 | Issue: 13 | Pages: 3268-3280

10.1182/bloodadvances.2025015793 | PMID 40101246 Get It

Abstract Allogeneic hematopoietic cell transplantation (allo-HCT) is potentially curative for older adults with hematologic malignancies. Concerns on nonrelapse mortality (NRM) in older adults limit allo-HCT utilization. We executed a prospective, observational study BMT-CTN 1704 (Blood and Marrow Transplant Clinical Trials Network) enrolling allo-HCT recipients aged ≥60 years from 49 centers in the United States. We analyzed associations between 13 measurements of older adult health and NRM within 1 year to construct a comprehensive health assessment risk model (primary-CHARM) using multivariate Fine-Gray model and grouped penalized variable selection. Two machine learning (ML) models (Cox and pseudo-value boosting) were also explored. Models’ performances were compared using area under the curve (AUC), with bootstrap and cross-validation sampling to correct for optimism, decision curve analysis (DCA), calibration, and Brier scores. Among 1105 patients with median age of 67 (range, 60-82) years who received allo-HCT, NRM was 14.4% and overall survival (OS) 71.7% at 1 year. Factors statistically selected for inclusion in primary-CHARM were higher comorbidity burden, lower albumin, higher C-reactive protein, older age, higher weight-loss percentage, lower patient-reported performance score, and cognitive impairment. Primary-CHARM scores were independently associated with higher NRM (hazard ratio [HR], 2.72; P < .0001) and worse OS (HR, 2.09; P < .0001). Bootstrap bias–corrected AUC for primary-CHARM was 0.591. Comparing primary-CHARM with HCT-comorbidity index and 2 ML-CHARM models, calibration, Brier score, and DCA analysis favored primary-CHARM. Primary-CHARM, with mostly simple and readily available parameters, risk stratifies older adults for allo-HCT. Adopting primary-CHARM in practice may promote broader use of HCT by quantifying risk and enhance the design of strategies to improve outcomes. This trial was registered at www.ClinicalTrials.gov as #NCT03992352.
International Liver Transplantation Society practice guideline update on portopulmonary hypertension
DuBrock, Hilary M. , Raevens, Sarah , Fallon, Michael B., Ramsay, Michael A. E. , Krowka, Michael J. , DuBrock, Hilary M , Savale, Laurent , Sitbon, Olivier , Kawut, Steven M. , Fallon, Michael B., Heimbach, Julie K. , Chadha, Ryan , Crespo, Gonzalo

Mayo Clinic

Liver Transplantation | March 17, 2025 | Volume: 32 | Issue: 2 | Pages: 296-314

10.1097/lvt.0000000000000600 | PMID 40094355 Get It

Portopulmonary hypertension (POPH), pulmonary arterial hypertension that develops in the setting of portal hypertension, has long been of significant interest to the pulmonary, cardiology, and hepatology communities. Optimal management of POPH has been challenging to define due to a lack of evidence from clinical trials regarding pulmonary arterial hypertension therapies and uncertainty regarding the role of liver transplantation (LT). Initially, the high risk of intraoperative and early post-transplant death in predominantly untreated patients with POPH tempered consideration of LT. More recently, the observation that POPH can improve, and sometimes even resolve, following LT, has led to reconsideration of the role of LT in selected patients. The first International Liver Transplantation Society (ILTS) POPH and hepatopulmonary syndrome practice guideline was a multidisciplinary consensus of expert opinions based on available evidence. Since that publication, hemodynamic definitions, management approaches, and POPH MELD exception criteria have evolved, and there have been new randomized controlled trials in POPH as well as studies regarding long-term outcomes. In order to ensure the guidelines remained current and reflected recent evidence, the original writing committee of the 2016 guidelines, leaders of the ILTS Cardiovascular Special Interest Group, and colleagues active in POPH research were invited to participate in the writing committee. In this document, approved for publication by the ILTS executive council, we provide an update to the prior guidelines with expert recommendations to guide and advance POPH management. Recommendations in these guidelines are based on expert opinion and available evidence and were agreed upon by consensus.
Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma
Banerjee, Rahul , Richards, Alicia, Midha, Shonali , Afrough, Aimaz , Anwer, Faiz , Atanackovic, Djordje , Bachanová, Veronika , Bhurtel, Jenny , Cicero, Kara I. , Davis, James A. , Dhakal, Binod , Ferreri, Christopher J. , Forsberg, Peter A. , Freeman, Ciara L. , Khouri, Jack , Kumar, Anupama, Liu, Yuxin , Mikkilineni, Lekha , Peres, Lauren C. , Purvey, Sneha , Raza, Shahzad , Sborov, Douglas W. , Shune, Leyla , Wagner, Charlotte B , Zanwar, Saurabh , Sidana, Surbhi , Patel, Krina K. , Kumar, Shaji , Lin, Yi , Martin, Thomas G. , Voorhees, Peter M. , Anderson, Larry D. , Cowan, Andrew J., Chhabra, Saurabh , Davis, James A , Dhakal, Binod , Freeman, Ciara L , Herr, Megan M. , Jain, Tania , Khouri, Jack , Kocoglu, Mehmet H , McGuirk, Joseph , Parrondo, Ricardo D , Pasvolsky, Oren , Sborov, Douglas W , Wagner, Charlotte , Zanwar, Saurabh S , Sidana, Surbhi , Patel, Krina , Kumar, Shaji K , Voorhees, Peter , Anderson, Larry D , Kaur, Gurbakhash , Bachanova, Veronika , Banerjee, Rahul , Raza, Shahzad , Anwer, Faiz , Atrash, Shebli , Beitinjaneh, Amer , Puglianini, Omar Castañeda , Chhabra, Saurabh , Dima, Danai , Jain, Tania , Janakiram, Murali , Kocoglu, Mehmet H. , Locke, Frederick L. , McGuirk, Joseph P. , Nadeem, Omar , Pasvolsky, Oren , Reshef, Ran , Richard, Shambavi , Rossi, Adriana , Hansen, Doris K. , Kaur, Gurbakhash

Mayo Clinic

Blood Advances | March 15, 2025 | Volume: 9 | Issue: 9 | Pages: 2336-2340

10.1182/bloodadvances.2025016131 | PMID 40088469 Get It

Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer
Yeku, Oladapo , Tan, Winston , Patnaik, Amita , LoRusso, Patricia , Richardson, Debra L. , Naqash, Abdul Rafeh , Lynam, Sarah , Kyriakopoulos, Christos E. , Dowlati, Afshin , Chamberlain, Marc C. , Yeku, Oladapo O , Tan, Winston W., Richardson, Debra L , Kyriakopoulos, Christos E , Naqash, Abdul Rafeh , Barve, Minal , Wang, Judy , Fu, Siqing , Gordon, Michael S. , Hubbard, Joleen M. , Kummar, Shivaani , Winer, Ira Seth

Mayo Clinic

Journal for ImmunoTherapy of Cancer | March 13, 2025 | Volume: 13 | Issue: 3 | Pages: e010959

10.1136/jitc-2024-010959 | PMID 40081941 Get It

Background Novel treatment options are required in patients with platinum-resistant ovarian cancer (PROC). Myeloid-derived suppressor cells promote a hostile tumor microenvironment and are associated with worse clinical outcomes in PROC. We evaluated the safety and preliminary efficacy of PY159, an agonist antibody to Triggering receptor expressed on myeloid cells-1 (TREM1) that reprograms immunosuppressive intratumoral myeloid cells, and PY314, an antagonist antibody to Triggering receptor expressed on myeloid cells-2 (TREM2) that depletes tumor-associated macrophages, as single agents and in combination with pembrolizumab in subjects with PROC. Methods PY159 and PY314 were individually evaluated in patients with PROC. Patients were treated with monotherapy (PY159 3 mg/kg or PY314 10 mg/kg), based on the recommended dose for expansion derived from the phase 1a studies. At the time of first progression, patients could continue study drug and crossover to combination therapy with pembrolizumab (200 mg) every 3 weeks at the discretion of the investigator. Disease assessment by Response Evaluation Criteria in Solid Tumor version 1.1 was performed every 6 weeks. Results 17 patients were enrolled in the PY159 study (median age 67, range 22–77; median prior therapies 6, range 2–18) and 16 patients in PY314 (median age 65.5, range 49–81; median prior therapies 4, range 2–10). 7 patients in PY159 and 8 patients in PY314 crossed over to combination therapy. Safety events included the following: treatment-related adverse events occurred in 15 patients (88.2%) in PY159 and 9 patients (56.3%) in PY314. Infusion-related reactions occurred in 6 patients (35.3%) in PY159 and 3 patients (18.8%) in PY314. Immune-related adverse events occurred in 13 patients (76.5%) in PY159 (arthralgias) and 1 patient (6.3%) in PY314 (diarrhea). Serious adverse events occurred in 6 patients (36.3%) in PY159 (1 related) and 12 patients (75%) in PY314 (all unrelated). The best radiographic response in PY159 was stable disease in 8/16 patients (50%; median 16 weeks, range 9–33), and in PY314, it was stable disease in 8/16 patients (50%; median 12 weeks, range 6–36). Median PFS was 2.76 months and 2.69 months in PY159 and PY314, respectively. There were no responses in the crossover arm. Conclusions Both PY159 and PY314 were well tolerated, with an acceptable safety profile, as both single agents and in combination with pembrolizumab. Both agents warrant further investigation in heavily pretreated PROC.
Assessment of Left‐Sided Hemodynamics With Exercise in Patients With Continuous Flow Left Ventricular Assist Device Support
Inglis, Sara S. , Schettle, Sarah , Villavicencio, Mauricio A. , Spencer, Philip J. , Stulak, John M., Kushwaha, Sudhir S. , Behfar, Atta, Rosenbaum, Andrew , Schettle, Sarah D , Rosenbaum, Andrew N , Inglis, Sara S , Tang, Paul C. , Behfar, Atta

Mayo Clinic

Artificial Organs | March 13, 2025 | Volume: 49 | Issue: 9 | Pages: 1462-1469

10.1111/aor.14995 | PMID 40078038 Get It

ABSTRACT Background Addition of left heart catheterization (LHC) to exercise protocols allows for a unique focus on parameters of systolic and diastolic responses to increased activity in patients with left ventricular assist device (LVAD) support. Methods A retrospective review was conducted of all consecutive adult patients who underwent LHC with exercise for any indication from June 2017 to June 2023. For all patients, the relationship between exercise and parameters of LV systolic and diastolic response was assessed. Patients were divided into two cohorts based on the indication for testing: hemodynamic optimization (Optim, n = 5) or weaning consideration (Wean, n = 3). Results Eight patients (88% male, median age 57 years (IQR 44, 65)) were included. LVEF was 45% (IQR 45, 56) in Wean and 25% (IQR 20, 42) in Optim. LV systolic work index (LVSWI) increased more rapidly over levels of exercise in Wean vs. Optim (slope 46.3 vs. −0.625; p = 0.044) and LVSWI rose more quickly at lower levels of LV end diastolic pressure (LVEDP) in Wean vs. Optim (slope 219.5 vs. −2.008; p = 0.0026). Pulse power index was higher in Wean patients at baseline (0.046 (IQR 0.04, 0.07) vs. 0.016 (IQR 0.001, 0.04); p = 0.14) and peak exercise (0.12 (IQR 0.12, 0.12) vs. 0.06 (IQR 0.03, 0.1); p = 0.29). Conclusions Patients with favorable remodeling on LVAD support have significantly improved LV systolic and diastolic responses to exercise and a trend of higher systemic pulsatility. Improving our understanding of LV‐LVAD interactions with activity may aid in future efforts to improve exercise tolerance through speed modulation.
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025
Greenberg, P, Stone, Richard M. , Al‐Kali, Aref , Bennett, John M. , Borate, Uma , Brunner, Andrew M. , Chai‐Ho, Wanxing , Curtin, Peter , Gaensler, Karin, Gahvari, Zhubin, Garcia-Manero, Guillermo, Jacoby, Meagan A., Keel, Sioḃán , Khanal, Rashmi, Maness, Lori J., McMahon, Christine M. , Odenike, Olatoyosi , Osman, Afaf, Sallman, David A. , Sayar, Hamid , Shallis, Rory M. , Tanaka, Tiffany , Kovach, Emily, Nguyen, Jamie , Hochstetler, Cindy, Osman, Afaf E.G. , Osman, Afaf E G , Abaza, Yasmin , Anand, Sarah , Ball, Brian J. , Dezern, Amy Elizabeth , Garcia‐Manero, Guillermo , Griffiths, Elizabeth A. , Haque, Tamanna Zohra , Jonas, Brian A. , Kishtagari, Ashwin , Madanat, Yazan F. , McCurdy, Shannon , Reddy, Vishnu , Singh, Abhay , Thota, Swapna , Kovach, Emily

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 12, 2025 | Volume: 23 | Issue: 3 | Pages: 66-75

10.6004/jnccn.2025.0013 | PMID 40073835 Get It

The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and comprehensive care of patients with MDS based on a review of recent clinical evidence that has led to important advances in treatment or has yielded new information on biologic factors that may have prognostic significance in MDS. The multidisciplinary panel of MDS experts is convened at least on an annual basis. During the annual meeting, the panel evaluates new and emerging data to inform their recommendations. These NCCN Guidelines Insights review the recent updates, including treatment recommendations both for lower-risk and higher-risk MDS, preference stratification of therapeutic agents, and emerging data on novel therapeutics.
Acute exogenous oestradiol augments endothelial and smooth muscle vasodilatory responsiveness in premenopausal but not postmenopausal females
Dillon, Gabrielle A. , Limberg, Jacqueline K. , Nicholson, Wayne T. , Joyner, Michael J. , Baker, Sarah E. , Miller, Virginia M. , Ranadive, Sushant M. , Harvey, Ronée E , Limberg, Jacqueline K , Nicholson, Wayne T , Joyner, Michael J , Baker, Sarah E , Harvey, Ronée E.

Mayo Clinic

The Journal of Physiology | March 11, 2025 | Volume: 603 | Issue: 8 | Pages: 2301-2311

10.1113/jp287719 | PMID 40012199 Get It

AbstractMenopause is associated with vascular dysfunction. During the menopausal transition, endogenous oestradiol concentrations diminish. Oestradiol is vasoprotective because it has direct and indirect effects on the vasculature. The present study aimed to determine the effect of acute exogenous oestradiol on endothelium‐dependent, endothelium independent and β2‐adrenergic receptor‐induced vasodilatation in females. Forearm blood flow (venous occlusion plethysmography) was measured during brachial intraarterial infusions of ACh (endothelium‐dependent agonist), sodium nitroprusside (endothelium independent agonist) and terbutaline (β2‐adrenergic receptor agonist) with and without concurrent infusion of 17β‐oestradiol. Nine young premenopausal (age: 26 ± 4 years) and nine postmenopausal (PM, age: 58 ± 4 years, 8 ± 1 years post‐menopause) females completed the study. Concurrent oestradiol infusion augmented the vasodilatory response to ACh, sodium nitroprusside and terbutaline in young premenopausal (all P < 0.05) but not older postmenopausal (all P > 0.05), females. Local infusion of exogenous 17β‐oestradiol augmented endothelial and smooth muscle microvascular vasodilatation in premenopausal but not postmenopausal, females. imageKey points Menopause is associated with vascular dysfunction. Because oestradiol has vasoprotective effects, the menopause‐associated drop in oestradiol concentrations is hypothesized to contribute to vascular dysfunction during the menopause transition. The present study shows that local infusion of exogenous oestradiol augmented microvascular vasodilatation in premenopausal but not postmenopausal females.
Liver Transplant Provider Perspectives on Posttransplant Management of Alcohol Use Disorder
Cote, Maria P. , Cloonan, Daniel , Li, Sienna, Razak, Shahaan S. , Singh, Ruby , Coe, Taylor M. , Zimbrean, Paula C. , Andrews, Sarah R., Ivkovic, Ana, Bartels, Stephen J. , Bethea, Emily D. , Yeh, Heidi , Dageforde, Leigh Anne , Bartels, Stephen , Chadha, Ryan , Bethea, Emily , Yeh, Heidi , Lim, Nicholas , Chadha, Ryan , Lim, Nicholas

Mayo Clinic

Transplantation Direct | March 11, 2025 | Volume: 11 | Issue: 4 | Pages: e1766

10.1097/txd.0000000000001766 | PMID 40078821 Get It

Background. Liver transplantation (LT) is the standard treatment for liver failure secondary to alcohol-associated liver disease, but limited literature and best practices exist for post-LT treatment of alcohol use disorder (AUD). This study explores current AUD management practices and providers’ perceived barriers to effective post-LT AUD management. Methods. A 45-item survey on post-LT AUD treatment practices was distributed to members of the American Society of Transplant Surgeons, the Association of Consult/Liaison Psychiatry Transplant Special Interest Group, and both the American Society of Transplantation’s Liver and Intestine Community of Practice and Psychosocial and Ethics Community of Practice discussion boards, between December 2021 and April 2022. Univariate analysis of categorical variables was performed using the chi-square test. Data were analyzed using center volume tertiles, country region, and provider professional activity. Results. Two hundred thirty-two respondents from 70 LT centers across all 11 United Network for Organ Sharing regions completed the survey. Half of the them were attending physicians and 16.4% were nurse coordinators. Most centers (84%) aimed for alcohol abstinence for all post-LT patients. Perceived barriers to AUD treatment efficacy included ongoing desire to drink (18%), denial about alcohol misuse (14.9%), and lack of posttransplant support (14%). Additionally, 62.1% of centers had no policy for prescribing medication-assisted therapy to treat AUD, and 32.7% of centers reported no center-level changes in AUD care. Providers identified primary needs as hiring additional mental health professionals (30.8%), dedicating specific staff to AUD care (24.7%), and standardizing psychiatric/psychological care in transplant clinics (17.2%). Conclusions. Despite the increasing volume of LT for alcohol-associated liver disease, significant perceived barriers to effective AUD treatment remain.